ClinicalTrials.gg
Status unknownNCT03668496Updated Mar 15, 2021

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

A Phase 3 interventional study of SHR-1210 and The placebo in Lung Cancer Squamous Cell, Lung Cancer Stage IV and PD-1 Antibody, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 53 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing camrelizumab in Lung Neoplasms — 2 open to participants now, 2 under way, none of them phase 3. camrelizumab · Lung Neoplasms.

Enrollment
2nd of 11
390 · median 59
Started
2018
with 1 other
Phase 3
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
4 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing camrelizumab in Lung Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 4th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 11 studies testing camrelizumab in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing camrelizumab in Lung Neoplasms, or all of them as a file.
02

Study summary

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with stage IV squamous non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of SHR-1210 + carboplatin + paclitaxel with placebo + carboplatin + paclitaxel in study population in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Read the detailed description

In this study, eligible subject will be randomized into study arm or control arm to accept study treatment. Subjects who randomized into control will have the opportunity to receive cross over treatment of SHR-1210 monotherapy after confirmed disease progression. Treatment cycles of chemotherapy will be 4-6 which will be decided by investigators.

03

Conditions studied

  • Lung Cancer Squamous Cell
  • Lung Cancer Stage IV
  • PD-1 Antibody
  • Chemotherapy Effect

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with histopathological diagnosis of squamous non-small cell lung cancer (SqNSCLC) and clinical stage IV
  2. has not received prior systemic treatment for NSCLC.
  3. Has a performance status of 0 or 1 on the (ECOG) Performance Status
  4. Has archived Tumor tissue samples
  5. Subject must have a measurable target lesion based on v1.1 .
  6. Has adequate organ function.
  7. Women of childbearing age must undergo a serological pregnancy test within 7 days before the first dose with negative results. Female subjects of reproductive age and male subjects whose spouse is a woman of reproductive age must agree to effective within 180 days after the study period and the last dose of the study drug.
  8. Subjects should be voluntarily participate in clinical studies and should be signed.

Exclusion criteria

Exclusion Criteria:

  1. active and meningeal
  2. uncontrollable tumor-related pain
  3. massive pleural effusion, peritoneal effusion or pericardial effusion which cannot be controlled by repeated drainage;
  4. radiotherapy to lung that is >30 Gy within 24 weeks before the first dose,
  5. imaging (CT or MRI) showed that the tumor invading the large vessels
  6. Known EGFR/ALK mutation.
  7. subjects with any known or suspected diseases
  8. subjects with known or suspected interstitial pneumonia;
  9. Subjects with severe cardiovascular and cerebrovascular diseases
  10. arteriovenous thrombosis events, such as deep vein thrombosis and pulmonary embolism, occurred within 3 months;
  11. female subjects who are pregnant or lactation or who plan to be pregnant during the study period;
  12. positive test;
  13. active
  14. evidence of active TB infection within 1 year before first dose;
  15. severe infection occurred within 4 weeks before the first dose
  16. patients with bleeding symptoms or with obvious bleeding tendency in the first month
  17. subjects who is on systemic immunogenic agents;
  18. a history of severe allergic reactions to other monoclonal antibodies/fusion proteins;
  19. History of severe allergic reactions to carboplatin or paclitaxel or their preventive drugs;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    SHR-1210 +chemotherapy

    subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles

    Drug: SHR-1210

  • Active comparator
    chemotherapy

    carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles

    Drug: The placebo

Interventions

  • Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.

  • DrugThe placebo

    in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: up to 24 month

Secondary outcomes

  1. Progression-free survival

    Progression-free survival (PFS) assessed by investigators according to RECIST V 1.1

    Time frame: up to 24 month

  2. Overall Survival (OS)

    defined as time from the randomized to the time of the patient's death from any reason assessed by researchers.

    Time frame: up to 24 month

  3. Objective Response Rate (ORR)

    The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1.

    Time frame: up to 24 month

  4. disease control rate (DCR)

    The proportion of patients who have achieved complete response, partial response and Stable disease assessed by investigators according to Recist v 1.1.

    Time frame: up to 24 month

  5. Duration of response (DoR)

    According to Recist v 1.1 accessed by investigators

    Time frame: up to 24 month

  6. Adverse events (AEs)

    All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 4.03

    Time frame: up to 24 month

07

Study locations

53 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230036, China
  • The Second Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui 230036, China
  • Anhui Chest Hospital
    Hefei, Anhui MD, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100000, China
  • The Fifth Medical Center of PLA Ceneral Hospital
    Beijing, Beijing 100000, China
  • The Seventh Medical Center of PLA Ceneral Hospital
    Beijing, Beijing 100000, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
  • 900TH Hospital of Joint Logistics Support Force
    Fuzhou, Fujian 350001, China
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong 510095, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Jieyang People's Hospital
    Jieyang, Guangdong 522000, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563003, China
  • Affiliated Hospital of Chengde Medical College
    Chengde, Hebei 067000, China
  • The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital)
    Shijiazhuang, Hebei 50000, China
  • Tangshan People's Hospital
    Tangshan, Hebei 63001, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430000, China
  • Tongji Hospital, Tongji Medical College of Hust
    Wuhan, Hubei 430000, China
  • Xiang yang Central Hospital
    Xiangyang, Hubei 441000, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
  • The Second Xiangya Hospital Of Central South University
    Changsha, Hunan 410008, China
  • The Third Xiangya Hospital Of Central South University
    Changsha, Hunan 410013, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210000, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu 214122, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225001, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin 130012, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130012, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • LinYi Cancer Hospital
    Linyi, Shandong 276001, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai 200433, China
  • Shanghai Pulmonary Hospital, Tongji University
    Shanghai, Shanghai 200433, China
  • Baoji Central Hospital
    Baoji, Shanxi 721000, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046000, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 030000, China
  • Shaanxi Provincial Cancer Hospital
    Xian, Shanxi 710061, China
  • Sichuan Provincial Cancer Hospital
    Chengdu, Sichuan 610000, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
    Kunming, Yunnan 650118, China
  • The First Affiliated Hospital,ZheJiang University
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital ZheJiang University School Of Medicine
    Hangzhou, Zhejiang 310018, China
  • ZheJiang Cancer Hospital
    HangZhou, Zhejiang 310022, China
  • The Second Affiliated Hospital of Zhejiang University of Medicine
    Hangzhou, Zhejiang 310052, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317000, China
08

References and documents

Publications

  • Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer. 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. PubMed 34980131 ↗
  • Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Yang Z, Shi W, Zou J, Zhou C; CameL-sq Study Group. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16. PubMed 34923163 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2020, 23 months.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 23 months is below that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 12, 2018
StartActual
Nov 9, 2018
Primary completionActual
Nov 6, 2020
CompletionEst.
Dec 31, 2021
Last update
Mar 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03668496
Responsible party
Sponsor
First posted
Sep 12, 2018
Start date
Nov 9, 2018
Primary completion
Nov 6, 2020
Completion
Dec 31, 2021 (estimated)
Last update
Mar 15, 2021

Study contacts

Jianjun Zou, MD, PhD
study director · Jiangsu HengRui Medicine Co., Ltd.
Caicun Zhou, MD, PhD
principal investigator · Tongji University, Shanghai Pulmonary Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion